Long-term effects of zonisamide in adult patients with intellectual disability.
drug-resistant epilepsy
intellectual disability
weight loss
zonisamide
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
06
04
2021
received:
05
02
2021
accepted:
13
04
2021
pubmed:
30
4
2021
medline:
2
10
2021
entrez:
29
4
2021
Statut:
ppublish
Résumé
This study aimed to evaluate the tolerability and efficacy of zonisamide (ZNS) in adult patients with drug-resistant epilepsy and intellectual disability (ID) at our epilepsy centre. By conducting a monocentric, open-label observational study based on standardized seizure records we retrospectively assessed 87 patients (39 female, mean age 40.6 ± 13.6, range 18-75 years) with ID and drug-resistant epilepsy. Evaluation, including calculation of retention rate, was performed for the intervals 3-6, 9-12 and 21-24 months after ZNS initiation. The Clinical Global Impressions Scale-Improvement (CGI-I) was used to detect qualitative changes in seizure severity and clinical status. Via regression analysis and the generalized estimating equations approach, we examined changes in body weight and impact of patient age also considering associations with other patient characteristics. The retention rate after 24 months was 60%. 28% discontinued ZNS therapy due to increasing seizure frequency, lack of efficacy or adverse events (AEs). Sedation (38%), language impairment (19%), challenging behaviour (10%), mild rash (10%) and dizziness (10%) were the commonest AEs. The responder rate was 40%, eight patients (9%) became seizure free. We found CGI-I to be dose-dependent. Regarding changes in body weight, we observed no difference between patients continuing or withdrawing ZNS therapy and responders or non-responders. Though, we identified older age as a significant risk factor for weight loss. Zonisamide may provide a safe and efficient therapeutic option for patients with ID and drug-resistant epilepsy. However, weight status should be carefully monitored, especially in elderly patients.
Substances chimiques
Anticonvulsants
0
Zonisamide
459384H98V
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-282Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry. 1996;61(5):433-443. https://doi.org/10.1136/jnnp.61.5.433
Preux P-M, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol. 2005;4(1):21-31. https://doi.org/10.1016/S1474-4422(04)00963-9
Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883-890. https://doi.org/10.1111/j.1528-1167.2009.02481.x
Robertson J, Hatton C, Emerson E, Baines S. Prevalence of epilepsy among people with intellectual disabilities: a systematic review. Seizure. 2015;29:46-62. https://doi.org/10.1016/j.seizure.2015.03.016
Pellock JM, Morton LD. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil Res Rev. 2000;6(4):309-323.10.1002/1098-2779(2000)6:4%3C309:aid-mrdd10%3E3.0.co;2-i
Doran Z, Shankar R, Keezer MR, et al. Managing anti-epileptic drug treatment in adult patients with intellectual disability: a serious conundrum. Eur J Neurol. 2016;23(7):1152-1157. https://doi.org/10.1111/ene.13016
Wagner AP, Croudace TJ, Bateman N, et al. Clinical services for adults with an intellectual disability and epilepsy: a comparison of management alternatives. PLoS One. 2017;12(7):e0180266. https://doi.org/10.1371/journal.pone.0180266
Kiani R, Tyrer F, Jesu A, et al. Mortality from sudden unexpected death in epilepsy (SUDEP) in a cohort of adults with intellectual disability. J Intellect Disabil Res. 2014;58(6):508-520. https://doi.org/10.1111/jir.12047
McGrother CW, Bhaumik S, Thorp CF, Hauck A, Branford D, Watson JM. Epilepsy in adults with intellectual disabilities: prevalence, associations and service implications. Seizure. 2006;15(6):376-386. https://doi.org/10.1016/j.seizure.2006.04.002
EMA. Zonegran EPAR product infromation: Summery of product characteristics. Published July 16, 2020. Accessed December 22, 2020. https://www.ema.europa.eu/en/documents/product-information/zonegran-epar-product-information_en.pdf
Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15(1):67-73. https://doi.org/10.1016/0920-1211(93)90011-u
Baulac M. Introduction to zonisamide. Epilepsy Res. 2006;68(Suppl 2):S3-9. https://doi.org/10.1016/j.eplepsyres.2005.11.004
Reimers A, Ljung H. An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. Expert Opin Pharmacother. 2019;20(8):909-915. https://doi.org/10.1080/14656566.2019.1595584
Iinuma K, Minami T, Cho K, Kajii N, Tachi N. Long-term effects of zonisamide in the treatment of epilepsy in children with intellectual disability [Abstract]. J Intellect Disabil Res. 1998;42(Suppl 1):68-73.
Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol. 2008;12(1):19-23. https://doi.org/10.1016/j.ejpn.2007.05.003
Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Epilepsy Res. 2009;83(2-3):112-116. https://doi.org/10.1016/j.eplepsyres.2008.10.012
Linden M, Baier D, Beitinger H, et al. Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy. The "Phase IV Research" Task-Force of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP). Pharmacopsychiatry. 1997;30(1 Suppl):65-70. https://doi.org/10.1055/s-2007-979520
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077. https://doi.org/10.1111/j.1528-1167.2009.02397.x
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522-530. https://doi.org/10.1111/epi.13670
Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.
Kleist A, Kerling F, Hamer H, Winterholler M. Lacosamide in patients with intellectual disability and refractory epilepsy. Acta Neurol Belg. 2019;119(3):423-430. https://doi.org/10.1007/s13760-019-01098-3
Andres E, Kerling F, Hamer H, Winterholler M. Behavioural changes in patients with intellectual disability treated with brivaracetam. Acta Neurol Scand. 2018;138(3):195-202. https://doi.org/10.1111/ane.12943
White JV, Guenter P, Jensen G, Malone A, Schofield M. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). JPEN J Parenter Enteral Nutr. 2012;36(3):275-283. https://doi.org/10.1177/0148607112440285
Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study. Epilepsia. 2014;55(10):1534-1543. https://doi.org/10.1111/epi.12749
Nakken KO, Lindstrøm P, Andersen H. Retention rate of zonisamide in intractable epilepsy. Acta Neurol Scand. 2015;131(5):268-274. https://doi.org/10.1111/ane.12379
Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16(4):296-304. https://doi.org/10.1016/j.seizure.2007.01.004
Mäkinen J, Peltola J, Raitanen J, Alapirtti T, Rainesalo S. Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market. J Neurol. 2017;264(7):1345-1353. https://doi.org/10.1007/s00415-017-8526-8
Kim DW, Choi K, Moon H-S, Oh J. Long-term retention rate of zonisamide in patients with epilepsy: an observational study. Clin Neuropharmacol. 2014;37(5):133-135. https://doi.org/10.1097/WNF.0000000000000046
Sackellares JC, Ramsay RE, Wilder BJ, Browne TR, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia. 2004;45(6):610-617. https://doi.org/10.1111/j.0013-9580.2004.11403.x
Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure. 2004;1:S59-S65. https://doi.org/10.1016/j.seizure.2004.04.009
Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005;46(1):31-41. https://doi.org/10.1111/j.0013-9580.2005.14704.x
Hoy SM. Zonisamide: a review of its use in the management of adults with partial seizures. Drugs. 2013;73(12):1321-1338. https://doi.org/10.1007/s40265-013-0093-4
Marinas A, Villanueva V, Giráldez BG, Molins A, Salas-Puig J, Serratosa JM. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord. 2009;11(1):61-66. https://doi.org/10.1684/epd.2009.0239
Lee HJ, Son JM, Mun J, Kim DW. Safety and efficacy of zonisamide in patients with epilepsy: a post-marketing surveillance study. J Epilepsy Res. 2015;5(2):89-95. https://doi.org/10.14581/jer.15015
Zhuo C, Jiang R, Li G, et al. Efficacy and tolerability of second and third generation anti-epileptic drugs in refractory epilepsy: a network meta-analysis. Sci Rep. 2017;7(1):2535. https://doi.org/10.1038/s41598-017-02525-2
Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SR, Jr, Hirsch LJ. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14(1):202-209. https://doi.org/10.1016/j.yebeh.2008.10.017
White JR, Walczak TS, Marino SE, Beniak TE, Leppik IE, Birnbaum AK. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology. 2010;75(6):513-518. https://doi.org/10.1212/WNL.0b013e3181eccfb5
Wandschneider B, Burdett J, Townsend L, et al. Effect of topiramate and zonisamide on fMRI cognitive networks. Neurology. 2017;88(12):1165-1171. https://doi.org/10.1212/WNL.0000000000003736
Krupa-Burtnik A, Zwierzyńska E, Pietrzak B. The effect of zonisamide on memory processes - A preclinical study. Epilepsy Behav. 2020;102:106659. https://doi.org/10.1016/j.yebeh.2019.106659
Faught E, Ayala R, Montouris GG, Leppik IE. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001;57(10):1774-1779. https://doi.org/10.1212/wnl.57.10.1774
Wellmer J, Wellmer S, Bauer J. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand. 2009;119(4):233-238. https://doi.org/10.1111/j.1600-0404.2008.01119.x
Trinka E, Giorgi L, Patten A, Segieth J. Safety and tolerability of zonisamide in elderly patients with epilepsy. Acta Neurol Scand. 2013;128(6):422-428. https://doi.org/10.1111/ane.12162
Romigi A, Femia EA, Fattore C, Vitrani G, Di Gennaro G, Franco V. Zonisamide in the management of epilepsy in the elderly. Clin Interv Aging. 2015;10:931-937. https://doi.org/10.2147/CIA.S50819